Trial Profile
A 52-Week, Open-Label, Extension Study of Pimavanserin for the Adjunctive Treatment of Schizophrenia
Status:
Recruiting
Phase of Trial:
Phase III
Latest Information Update: 02 Feb 2024
Price :
$35
*
At a glance
- Drugs Pimavanserin (Primary)
- Indications Schizophrenia
- Focus Adverse reactions
- Sponsors Acadia Pharmaceuticals
- 01 Feb 2024 Planned number of patients changed from 550 to 993.
- 22 Nov 2023 This trial has been completed in Lithuania, according to the European Clinical Trials Database record.
- 23 Dec 2020 Planned End Date changed from 1 May 2021 to 1 Mar 2024.